BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Nso N, Antwi-Amoabeng D, Beutler BD, Ulanja MB, Ghuman J, Hanfy A, Nimo-Boampong J, Atanga S, Doshi R, Enoru S, Gullapalli N. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World J Cardiol 2020; 12(11): 584-598 [PMID: 33312443 DOI: 10.4330/wjc.v12.i11.584]
URL: https://www.wjgnet.com/1949-8462/full/v12/i11/584.htm
Number Citing Articles
1
Ja-Young Han, Young-Eun Seo, Jae-Hee Kwon, Jae Hyun Kim, Myeong Gyu Kim. Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS DatabaseJournal of Clinical Medicine 2024; 13(5): 1218 doi: 10.3390/jcm13051218
2
Yiran Rong, John P. Bentley, Kaustuv Bhattacharya, Yi Yang, Yunhee Chang, Sally Earl, Sujith Ramachandran. Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancerCancer Medicine 2024; 13(1) doi: 10.1002/cam4.6879
3
Chun-Ka Wong, Tsun-Ho Lam, Song-Yan Liao, Yee-Man Lau, Hung-Fat Tse, Benjamin Y. F. So. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment ImplicationsBiomedicines 2023; 11(1): 107 doi: 10.3390/biomedicines11010107
4
Samuel Peter Heilbroner, Reed Few, Tomas G Neilan, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus. Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approachJournal for ImmunoTherapy of Cancer 2021; 9(10): e002545 doi: 10.1136/jitc-2021-002545
5
Chin-Chin Ho, Shang-Liang Wu, Han-Yi Tsai, Yu-Wen Hu, Yuh-Lih Chang. A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patientsJournal of the Chinese Medical Association 2023; 86(5): 499 doi: 10.1097/JCMA.0000000000000910
6
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico Van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke. Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter StudyPharmaceuticals 2023; 16(4): 625 doi: 10.3390/ph16040625
7
Umut Selamet, Rebecca S. Ahdoot, Reed Salasnek, Lama Abdelnour, Ramy M. Hanna. Onconephrology: mitigation of renal injury in chemotherapy administrationCurrent Opinion in Nephrology & Hypertension 2024; 33(2): 257 doi: 10.1097/MNH.0000000000000960
8
Mandana Chitsazan, Ahmad Amin, Luisa Ladel, Alyza Baig, Mitra Chitsazan. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive ReviewCritical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2023; 22(3): 69 doi: 10.1097/HPC.0000000000000327
9
Sarah E. Mudra, Danny L. Rayes, Ankit Agrawal, Ashwin K. Kumar, Jason Z. Li, Meredith Njus, Kevin McGowan, Kazi A. Kalam, Charalompos Charalampous, Mary Schleicher, Muhammad Majid, Alvena Syed, Abdullah Yesilyaprak, Allan L. Klein. Immune checkpoint inhibitors and pericardial disease: a systematic reviewCardio-Oncology 2024; 10(1) doi: 10.1186/s40959-024-00234-0
10
Tzu-Fei Wang, Alok A. Khorana, Marc Carrier. Thrombotic Complications Associated with Immune Checkpoint InhibitorsCancers 2021; 13(18): 4606 doi: 10.3390/cancers13184606
11
Virginia S. Hahn, Kathleen W. Zhang, Lova Sun, Vivek Narayan, Daniel J. Lenihan, Bonnie Ky. Heart Failure With Targeted Cancer TherapiesCirculation Research 2021; 128(10): 1576 doi: 10.1161/CIRCRESAHA.121.318223
12
Omoruyi Credit Irabor, Nicolas Nelson, Yash Shah, Muneeb Khan Niazi, Spencer Poiset, Eugene Storozynsky, Dinender K. Singla, Douglas Craig Hooper, Bo Lu. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitorsFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.940127
13
Jing Wu, Tingting Ni, Rong Deng, Yan Li, Qin Zhong, Fei Tang, Qi Zhang, Chunju Fang, Yingbo Xue, Yan Zha, Yu Zhang. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysisFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1065510
14
Masayoshi Oikawa, Takafumi Ishida, Yasuchika Takeishi. Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestationJournal of Cardiology 2023; 81(3): 253 doi: 10.1016/j.jjcc.2022.04.006
15
Walid Shalata, Rachel Steckbeck, Amjad Abu Salman, Omar Abu Saleh, Ashraf Abu Jama, Zoé Gabrielle Attal, Sondos Shalata, Hilmi Alnsasra, Alexander Yakobson. Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the LiteratureMedicina 2024; 60(2): 224 doi: 10.3390/medicina60020224
16
Liga Vidusa, Oskars Kalejs, Aija Maca-Kaleja, Ilze Strumfa. Role of Endomyocardial Biopsy in Diagnostics of MyocarditisDiagnostics 2022; 12(9): 2104 doi: 10.3390/diagnostics12092104
17
Alessandro Inno, Andrea Chiampan, Laura Lanzoni, Matteo Verzè, Giulio Molon, Stefania Gori. Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer PatientsFrontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.652186
18
Feifei Wang, Qi Wei, Xinan Wu. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting systemFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.986357
19
Bingxun Li, Mingjie Lin, Lin Wu. Drug-induced AF: Arrhythmogenic Mechanisms and Management StrategiesArrhythmia & Electrophysiology Review 2024; 13 doi: 10.15420/aer.2023.24
20
Honglin Li, Deting Han, Lei Zhang, Xiaoteng Feng, Huijie Li, Feiran Yang, Lucheng Song, Xiurong Li. Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic ReviewImmunotherapy 2022; 14(7): 577 doi: 10.2217/imt-2021-0223
21
Diana Larisa Mocan-Hognogi, Sebastian Trancǎ, Anca Daniela Farcaş, Radu Florin Mocan-Hognogi, Andrada Viorica Pârvu, Anca Simona Bojan. Immune Checkpoint Inhibitors and the HeartFrontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.726426
22
Zhuo Ma, Ximu Sun, Yi Zhang, Hao Li, Dan Sun, Zhuoling An, Yuhui Zhang. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled TrialsThrombosis and Haemostasis 2022; 122(10): 1757 doi: 10.1055/s-0042-1749185
23
Jiayi Chen, Shuang Liu, Zheng Ruan, Kankan Wang, Xiaodong Xi, Jianhua Mao. Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding riskBlood Reviews 2024; : 101220 doi: 10.1016/j.blre.2024.101220
24
Giselle Alexandra Suero-Abreu, Markella V. Zanni, Tomas G. Neilan. Atherosclerosis With Immune Checkpoint Inhibitor TherapyJACC: CardioOncology 2022; 4(5): 598 doi: 10.1016/j.jaccao.2022.11.011
25
Younan Samuel, Aswin Babu, Foteini Karagkouni, Ayden Ismail, Sunyoung Choi, Stergios Boussios. Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision MedicineCurrent Issues in Molecular Biology 2023; 45(10): 8337 doi: 10.3390/cimb45100526
26
Michał Gawlik, Jakub Michal Zimodro, Aleksandra Gąsecka, Krzysztof J. Filipiak, Sebastian Szmit. Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 GuidelinesCurrent Oncology Reports 2023; 25(10): 1107 doi: 10.1007/s11912-023-01445-x